Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

AD/PD 2023

Browse Popular Uploads...

View all
10:55
Novel combination therapy PrimeC in ALS: biomarker data & launch of Phase II trial
Shiran Salomon-Zimri • 27 Mar 2023
7:08
Long-term follow up of LECIG use in Sweden
Dag Nyholm • 24 Mar 2023
6:10
Latest developments in Parkinson’s disease biomarkers
Andrea Pilotto • 23 Mar 2023
1:30
Cell- and gene-therapy landscape in Parkinson’s disease
Emma Lane • 29 Mar 2023

Parkinson's Disease Treatment... What's on the Horizon?

View all
2:37
Novel brain penetrant capsids for Parkinson’s disease gene therapy
Todd Carter • 29 Mar 2023
2:02
Phase I study of selnoflast to slow neurodegeneration in Parkinson’s disease
Gennaro Pagano • 5 Apr 2023
2:23
Key questions for cell and gene therapy trials in Parkinson’s disease
Emma Lane • 29 Mar 2023
2:34
Ongoing efforts to improve levodopa-based treatments in Parkinson’s disease
Dag Nyholm • 24 Mar 2023

Expert Perspectives

View all
1:17
Highlights of the AD/PD conference 2023
Tiago Outeiro • 25 Apr 2023
1:44
What is the significance of gastrointestinal involvement in Parkinson’s disease?
Dag Nyholm • 24 Mar 2023
2:03
What is the future of immunotherapy in Parkinson’s disease?
Gennaro Pagano • 5 Apr 2023
2:07
Future of tau-targeting immunotherapies in Alzheimer’s disease
Todd Carter • 29 Mar 2023
The content of VJNeurology is intended for healthcare professionals